新生血管性年龄相关性黄斑变性玻璃体腔注射治疗的不依从与不持续:混合方法系统综述
本系统综述评估了新生血管性年龄相关性黄斑变性(nAMD)患者对玻璃体腔抗VEGF注射治疗不依从和不持续的风险因素。共纳入37项研究,发现不持续发生较早,24个月内高达50%患者停止治疗,不依从率为32%至95%,定义异质性大。多种因素影响依从性,包括病情、治疗、患者、社会/经济及医疗系统层面,改善策略证据有限但有效。
要点
- nAMD抗VEGF治疗不持续发生早,24个月内高达50%患者停止治疗。
- 不依从率高,报告范围为32%至95%,但定义异质性大。
- 基线视力较低和治疗反应较差是与病情相关的中等质量证据因素。
核心结论
- 认识nAMD患者不依从和不持续的相关因素有助于识别高危人群并改善真实世界结局。
- 需要进一步工作制定统一标准并建立高质量证据以支持可实施的干预措施。
研究设计与样本
- 系统综述,纳入报告抗VEGF治疗不依从和不持续因素的研究及改善策略的研究。
- 共筛选1284篇摘要,全文评估124篇,最终纳入37项研究。
- 采用Cochrane综述方法进行试验 eligibility 和数据提取,使用混合方法评估工具评估偏倚风险,采用GRADE CERQual工具评价证据确定性。
主要发现
- 不依从和不持续的定义各异或未报告。
- 不持续发生较早,24个月内高达50%患者停止治疗。
- 不依从率高,报告范围为32%至95%,因定义异质性证据确定性降为中等。
- 多种因素决定不依从和不持续,包括病情、治疗、患者、社会/经济及医疗系统/团队层面。
- 中等质量证据指出基线视力较低和治疗反应较差是与病情相关的变量。
关键数值与推荐
- 不持续:24个月内高达50%患者停止治疗。
- 不依从:报告范围为32%至95%。
- 基线视力较低和治疗反应较差为中等质量证据的病情相关因素。
临床怎么用
- 了解不依从和不持续的相关因素可帮助识别高危患者。
- 针对可纠正因素(如缺乏交通、患者期望不匹配)可能改善依从性。
- 改善依从性和持续性的策略证据有限,但现有证据显示有效。
局限性
- 不依从和不持续的定义各异或未报告,导致异质性。
- 其他因素效应的确定性较低,主要因样本量小和回顾性评估的潜在偏倚。
- 改善依从性和持续性的策略证据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
TOPIC: Systematic review of risk factors for nonadherence and nonpersistence to intravitreal anti-vascular endothelial growth factor (VEGF) injection therapy for neovascular age-related macular degeneration (nAMD). CLINICAL RELEVANCE: Lack of adherence (nonadherence) or undertreatment (nonpersistence) with respect to evidence from clinical trials remains a significant barrier to optimizing real-world outcomes for patients with nAMD. Contributing factors and strategies to address this are poorly understood. METHODS: Studies that reported factors for nonadherence and nonpersistence to anti-VEGF therapy as well as studies examining strategies to improve this were included. Trial eligibility and data extraction were conducted according to Cochrane review methods. Risk of bias was assessed using the Mixed Method Assessment Tool and certainty of evidence evaluated according to the GRADE Confidence in the Evidence from Reviews of Qualitative Research tool. Data were collated descriptively. RESULTS: Of the 1284 abstract results screened, 124 articles were assessed in full and 37 studies met the inclusion criteria. Definitions of nonadherence and nonpersistence varied or were not reported. Nonpersistence occurred early, with up to 50% of patients stopping treatment by 24 months. High rates of nonadherence were similarly reported, occurring in 32% to 95% of patients. Certainty of this finding was downgraded to a moderate level because of the heterogeneity in definitions used across studies. Multiple factors determine nonadherence and nonpersistence, including at the condition, therapy, patient, social/economic, and health systems/healthcare team levels. Moderate quality evidence points to lower baseline vision and poorer response to treatment as condition-related variables. The effects of other factors were of lower certainty, predominantly due to small numbers and potential biases in retrospective assessment. Although many factors are not modifiable (e.g., patient comorbidity), other factors are potentially correctable (e.g., lack of transport or mismatched patient expectations). Evidence on strategies to improve adherence and persistence is limited, but where available, these have proven effective. CONCLUSIONS: Awareness of factors related to poor patient adherence and persistence in nAMD could help identify at-risk populations and improve real-world outcomes. Further work is required to develop uniform definitions and establish high-quality evidence on interventions that can be easily implemented.
引用
- Okada M, Mitchell P, Finger RP, et al. Nonadherence or Nonpersistence to Intravitreal Injection Therapy for Neovascular Age-Related Macular Degeneration: A Mixed-Methods Systematic Review. Ophthalmology. 2020. PMID: 32763265. doi:10.1016/j.ophtha.2020.07.060
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。